SGLT2 inhibition and heart failure—current concepts

Overview of attention for article published in Heart Failure Reviews, April 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

patent: 7 patents

Citations

dimensions_citation: 27 Dimensions

Readers on

mendeley: 105 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 7 patents that reference this research output.

Methods of treating heart failure with reduced ejection fraction

Grant US-11903955-B2

United States of America

Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in…

Grant US-11826378-B2

United States of America

Methods of treating HFpEF employing dapagliflozin and compositions comprising the same

Grant AU-2019304032-B2

Australia

USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN…

Application WO-2021165177-A1

World Intellectual Property Organisation (WIPO)

Methods of treating heart failure with reduced ejection fraction

Grant US-10973836-B2

United States of America

Methods of treating HFpEF using dapagliflozin and compositions comprising dapagliflozin

Application CN-112512530-A

China

METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME

Application WO-2020016335-A1

World Intellectual Property Organisation (WIPO)